TY - JOUR
T1 - Synthesis and Cytotoxicity Studies of Br-Substituted Salphen Organic Compounds
AU - Zelada-Guillén, Gustavo A.
AU - Ríos-Arce, Jesús A.
AU - Leyva-Peralta, Mario A.
AU - Flores-Álamo, Marcos
AU - Gálvez-Ruíz, Juan Carlos
AU - Calderón, Kadiya
AU - Escárcega-Bobadilla, Martha V.
N1 - Publisher Copyright:
© 2023 The Authors. Chemistry & Biodiversity published by Wiley-VHCA AG, Zurich, Switzerland.
PY - 2023/5
Y1 - 2023/5
N2 - We present the synthesis and characterization of organic Salphen compounds containing bromine substituents at the para/ortho-para positions, in their symmetric and non-symmetric versions, and describe the X-ray structure and full characterization for the new unsymmetrical varieties. We report for the first time antiproliferative activity in metal-free brominated Salphen compounds, by evaluations in four human cancer cell lines, cervix (HeLa), prostate (PC-3), lung (A549) and colon (LS 180) and one non-cancerous counterpart (ARPE-19). We assessed in vitro cell viability against controls using the MTT assay ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)) and determined the concentration required for 50 % growth inhibition (IC50), together with their selectivity vs. non-cancerous cells. We found promising results against prostate (9.6 μM) and colon (13.5 μM) adenocarcinoma cells. We also found a tradeoff between selectivity (up to 3-fold vs. ARPE-19) and inhibition, depending upon the symmetry and bromine-substitution of the molecules, showing up to 20-fold higher selectivity vs. doxorubicin controls.
AB - We present the synthesis and characterization of organic Salphen compounds containing bromine substituents at the para/ortho-para positions, in their symmetric and non-symmetric versions, and describe the X-ray structure and full characterization for the new unsymmetrical varieties. We report for the first time antiproliferative activity in metal-free brominated Salphen compounds, by evaluations in four human cancer cell lines, cervix (HeLa), prostate (PC-3), lung (A549) and colon (LS 180) and one non-cancerous counterpart (ARPE-19). We assessed in vitro cell viability against controls using the MTT assay ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)) and determined the concentration required for 50 % growth inhibition (IC50), together with their selectivity vs. non-cancerous cells. We found promising results against prostate (9.6 μM) and colon (13.5 μM) adenocarcinoma cells. We also found a tradeoff between selectivity (up to 3-fold vs. ARPE-19) and inhibition, depending upon the symmetry and bromine-substitution of the molecules, showing up to 20-fold higher selectivity vs. doxorubicin controls.
KW - Brominated salphen compounds
KW - Schiff bases
KW - antiproliferative activity
KW - metal-free anti-cancer drugs
KW - selectivity index
UR - http://www.scopus.com/inward/record.url?scp=85156184252&partnerID=8YFLogxK
U2 - 10.1002/cbdv.202200972
DO - 10.1002/cbdv.202200972
M3 - Artículo
C2 - 37058554
AN - SCOPUS:85156184252
SN - 1612-1872
VL - 20
JO - Chemistry and Biodiversity
JF - Chemistry and Biodiversity
IS - 5
M1 - e202200972
ER -